Why strong science loses the room. You're fluent in one language; the investor is listening in another. Here's the gap — and how to cross it.
It's a translation problem, not a pitch problem. The work isn't saying it louder — it's saying it in the language the room is listening for.
Open with the outcome and who it's for — not the mechanism. The science is how you deliver the change; it isn't the opening line. If the first thing they hear is what's different in the world, they lean in.
Name how big it could get, and the realistic route from lab to product. Investors fund a believable path, not just a breakthrough. A roadmap with milestones tells them you've thought past the discovery.
They expect science risk — that's the bet they came to make. What scares them is everything after: the market, the team, the route to revenue. Reduce that, and the science risk becomes the only risk left — the one they actually want to take.
"We help [who] [achieve what outcome] using [the science, in plain words] — a [market] opportunity."
"We've developed a novel platform for targeted gene activation with high specificity."
"We can switch on the body's own defenses against [condition] — a [$X] market — and we've already shown the core science works in the lab."
Translate, don't dumb down. The science still matters — it just isn't the headline. You're changing the order things are said, not hiding the depth.
Taking investor feedback verbatim into the negotiation. A VC asks for the moon because that's their job — hear the intent, not the literal terms, or you'll negotiate against yourself before you reach the table.